JenaValve Technology said today that it closed a $26.5 million Series C round for the replacement heart valve it’s developing. Irvine, Calif.-based JenaValve said the round was co-led by RMM (Rudi Mariën) and Valiance and included existing backers Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management and VI Partners. The proceeds are earmarked […]
Self-driving vehicle development company Clearpath Robotics said today it picked up Intuitive Surgical‘s (NSDQ:ISRG) director of design & management Mike Hanuschik. Hanuschik led the design and product management for Intuitive Surgical’s flagship da Vinci surgical robot system, the market leading robotic surgery platform. The da Vinci is used in over 500,000 procedures annually, according to […]
JenaValve said this week that it tapped Victoria Carr-Brendel, former general manager of Boston Scientific‘s (NYSE:BSX) Bayer Interventional business, as its new chief executive officer. Carr-Brendel will replace Jan Keltjens, who served as interim CEO of the transcatheter aortic valve repair-focused company since January 2015. Keltjens will remain with the company as chairman of the board, JenaValve said. […]
JenaValve tapped a medtech veteran with a string of successful exits behind him as interim chairman & CEO, replacing another medical device vet, David Drachman, after just 7 months.
UPDATED Nov. 18, 2014, with a clarification from JenaValve.
JenaValve Technology yesterday reported adding nearly $17.3 million to a Series C funding round, bring the total raise to nearly $79.8 million.
JenaValve, fresh off of a $63 million funding round, said it won CE Mark approval in the European Union for its transapical replacement heart valve to treat aortic insufficiency, also known as aortic regurgitation.
The expanded approval makes JenaValve’s transcatheter aortic replacement valve implant the world’s only such device approved to treat high-risk or inoperable aortic insufficiency, according to a press release.
A pair of Canadian women, aged 87 and 71, became the 1st non-European patients to receive treatment with JenaValve Technology‘s new transcatheter aortic valve implantation system.
JenaValve’s 2nd-generation transapical TAVI device is surgically implanted in the natural aortic valve cavity, and features an anchoring and clipping mechanism to ensure the device stays in place.